Insight, China's Pharmaceutical Industry

JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In‑House Lentiviral Vector Production

JW (Cayman) Therapeutics Co. Ltd (HKG: 2126) announced today that the National Medical Products Administration...

Acotec Scientific Receives FDA 510(k) Clearance for Endovenous Radiofrequency Ablation System

Fineline Cube Oct 10, 2025

Acotec Scientific Holdings Limited (HKG: 6669) announced on October 7, 2025 that its Endovenous Radiofrequency Ablation System...

Company Drug

Beijing Luzhu Biotechnology Completes U.S. Phase 1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity

Fineline Cube Oct 10, 2025

Beijing Luzhu Biotechnology Co., Ltd. (HKG: 2480) announced today that its Phase 1 clinical trial of...

Company Drug

Huadong Medicine Secures NMPA Trial Approval for HDM2017, a CDH17‑Targeting ADC

Fineline Cube Oct 10, 2025

China‑based Huadong Medicine Co., Ltd. (SHE: 000963) announced that its novel antibody‑drug conjugate (ADC), HDM2017...

Company Deals

Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler

Fineline Cube Oct 10, 2025

Hangzhou‑based Chance Pharmaceuticals Co., Ltd. has inked an exclusive commercialization agreement with Shanghai‑listed Huadong Medicine...

Company

Takeda Shuts Down Cell‑Therapy Program, Eyes External Collaboration for γδ T‑Cell Platform

Fineline Cube Oct 10, 2025

Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) announced today that it is discontinuing all...

Company Medical Device

Mirxes Secures China’s First Blood‑Test Approval for Gastric‑Cancer Screening

Fineline Cube Oct 9, 2025

Mirxes Holding Company Limited (HKG: 2629) announced that its flagship in‑vitro diagnostic (IVD) test, GASTROClear,...

Company Medical Device

Jenscare Secures LuX‑Valve Approval for Transjugular Tricuspid Replacement in Greater Bay Area

Fineline Cube Oct 9, 2025

Jenscare Scientific Co., Ltd (HKG: 9877) announced that its LuX‑Valve Plus transjugular tricuspid valve replacement...

Company Drug

Roche Secures FDA Approval for Tecentriq‑Lurbinectedin Combo in ES‑SCLC

Fineline Cube Oct 9, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that the U.S. Food and Drug Administration (FDA)...

Company Drug

Eli Lilly to Invest $1B in India, Launch New Hyderabad Manufacturing Hub

Fineline Cube Oct 9, 2025

Eli Lilly & Co. (NYSE: LLY) has announced a commitment to invest more than USD 1 billion...

Company Drug

Walvax Biotech Wins Jordan FDA Approval for 13‑Valent Pneumococcal Vaccine

Fineline Cube Oct 9, 2025

China‑based Walvax Biotechnology Co., Ltd. (SHE: 300142) has secured market approval from the Jordan Food...

Company Drug

Northeast Pharma Secures NMPA Approval for DCTY0801 Injection Targeting EGFRvIII‑Positive Brain Gliomas

Fineline Cube Oct 9, 2025

China‑based Northeast Pharmaceutical Group Co., Ltd. (SHE: 000597) has announced that its chimeric antigen receptor...

Company Deals Drug

InnoCare, Zenas, Orelabrutinib: $2 B Licensing Deal Fuels MS Therapeutic Pipeline

Fineline Cube Oct 9, 2025

InnoCare Pharma Limited (HKG: 9969) announced a landmark exclusive license and subscription agreement with Zenas...

Company Drug

Hengrui, SHR‑4298, RAS: China Approves Two Novel Anti‑Tumor Drugs for Clinical Trials

Fineline Cube Oct 9, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration...

Company Drug

Shanghai Fosun Secures NMPA Approval for HLX43 + HLX07 Combination in Advanced Solid Tumors

Fineline Cube Oct 9, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the National Medical Products Administration...

Company Drug

RemeGen & Santen Announce CDE Acceptance of RC28‑E for Diabetic Macular Edema

Fineline Cube Sep 30, 2025

China‑based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) and Japan’s Santen Pharmaceutical Co., Ltd. confirmed...

Company Deals

AstraZeneca Announces Dual‑Market Direct Listing on NYSE, Harmonising Global Share Structure

Fineline Cube Sep 30, 2025

AstraZeneca plc (AZ; NASDAQ: AZN) has unveiled a plan to standardise its share‑listing structure across...

Company Deals Drug

C‑MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First‑In‑Class P‑glycoprotein Inhibitor Encequidar

Fineline Cube Sep 30, 2025

C‑MER Medical Holdings Limited (HKG: 3309) announced that its joint‑venture arm, Health Hope Pharma Limited...

Policy / Regulatory

NMPA Announces Import of Commercial‑Scale Pre‑Approval Overseas Drugs

Fineline Cube Sep 30, 2025

The National Medical Products Administration (NMPA) has issued a new regulatory framework, titled “Announcement on...

Company Deals

MicroPort Announces $680 Million Merger with CRM Cayman, Expanding Cardio‑Medical Footprint

Fineline Cube Sep 30, 2025

MicroPort Scientific Corporation (HKG: 0853) disclosed that CRM Cayman, MicroPort CardioFlow Medtech Corporation, and MicroPort CardioFlow...

Insight, China's Pharmaceutical Industry

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In‑House Lentiviral Vector Production

Acotec Scientific Receives FDA 510(k) Clearance for Endovenous Radiofrequency Ablation System

Beijing Luzhu Biotechnology Completes U.S. Phase 1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity

Huadong Medicine Secures NMPA Trial Approval for HDM2017, a CDH17‑Targeting ADC

Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler

Takeda Shuts Down Cell‑Therapy Program, Eyes External Collaboration for γδ T‑Cell Platform

Mirxes Secures China’s First Blood‑Test Approval for Gastric‑Cancer Screening

Jenscare Secures LuX‑Valve Approval for Transjugular Tricuspid Replacement in Greater Bay Area

Roche Secures FDA Approval for Tecentriq‑Lurbinectedin Combo in ES‑SCLC

Eli Lilly to Invest $1B in India, Launch New Hyderabad Manufacturing Hub

Walvax Biotech Wins Jordan FDA Approval for 13‑Valent Pneumococcal Vaccine

Northeast Pharma Secures NMPA Approval for DCTY0801 Injection Targeting EGFRvIII‑Positive Brain Gliomas

InnoCare, Zenas, Orelabrutinib: $2 B Licensing Deal Fuels MS Therapeutic Pipeline

Hengrui, SHR‑4298, RAS: China Approves Two Novel Anti‑Tumor Drugs for Clinical Trials

Shanghai Fosun Secures NMPA Approval for HLX43 + HLX07 Combination in Advanced Solid Tumors

RemeGen & Santen Announce CDE Acceptance of RC28‑E for Diabetic Macular Edema

AstraZeneca Announces Dual‑Market Direct Listing on NYSE, Harmonising Global Share Structure

C‑MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First‑In‑Class P‑glycoprotein Inhibitor Encequidar

NMPA Announces Import of Commercial‑Scale Pre‑Approval Overseas Drugs

MicroPort Announces $680 Million Merger with CRM Cayman, Expanding Cardio‑Medical Footprint

You Missed

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404